Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL
Pharma & biotech2018-06-29
21 Views
The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
2019 Taiwan Open of Surfing kicks off on November 23rd at Taitung Jinzun
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services
